Kurs & Likviditet
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Informationsteknik |
| Industri | Programvara |
Aiforia Technologies Plc Press Release April 9, 2024 at 09:00 a.m. EEST
Richard Haworth joins Aiforia’s Scientific Advisory Board
Aiforia welcomes Richard Haworth to its Scientific Advisory Board. He is a Founder of RosettaPath Ltd., providing digital, research, and toxicologic pathology consultancy across various sectors including biotech, pharmaceuticals, contract research organizations (CROs), software vendors, and academia. Prior to RosettaPath, Haworth led the Global Pathology team within Clinical Pharmacology and Safety Sciences at AstraZeneca and before that, he served as Head of the UK Pathology department at GSK. He earned his veterinary medicine degree from the University of Cambridge and completed a PhD at Oxford University, focusing on experimental pathology and immunology. Haworth holds board certifications in veterinary pathology (FRCPath, Diplomate of the European College of Veterinary Pathologists) and toxicology (Diplomate of the American Board of Toxicology). In March 2024, Haworth achieved accreditation as a Full Fellow of the International Academy of Toxicologic Pathology.
“We are excited to have Richard join our Scientific Advisory Board. His extensive background encompasses hands-on experience in utilizing image analysis software as a pathologist. He has contributed to discovery research, safety assessment (including toxicology studies), and translational efforts involving human tissue analysis for the identification of exploratory biomarkers. Moreover, Haworth brings senior leadership experience from the pharmaceutical industry, coupled with a profound understanding of decision-making data within diverse digital imaging workflows. Richard's input will not only support our product development but also fortify our go-to-market strategies, enhancing our operational excellence", says Jukka Tapaninen, CEO of Aiforia.
Haworth comments on his motivation to join Aiforia’s Scientific Advisory Board: "I'm impressed by how intuitive Aiforia Create software is and how swiftly it can generate an AI model tailored to specific needs. Aiforia covers a wide range of AI-based image analysis algorithms across research, preclinical, and clinical applications. It’s this extensive scope that excites me about collaborating with the company.”
More information on the members of the Scientific Advisory Board is available on the company's website at https://www.aiforia.com/about-us/our-team.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com